Effectiveness of Prevnar [pneumococcal 7 valent CRM197 vaccine conjugate] in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

Trial Profile

Effectiveness of Prevnar [pneumococcal 7 valent CRM197 vaccine conjugate] in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2012

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 30 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 03 Jun 2011 Additional lead trial center identified and company added as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top